{"id":8491,"date":"2026-11-06T15:10:18","date_gmt":"2026-11-06T14:10:18","guid":{"rendered":"https:\/\/oncopeptides.com\/?post_type=news&p=8491"},"modified":"2026-11-10T15:25:52","modified_gmt":"2026-11-10T14:25:52","slug":"redeye-intervjuar-oncopeptides-i-samband-med-q3-rapporten","status":"publish","type":"news","link":"https:\/\/oncopeptides.com\/sv\/nyheter\/redeye-intervjuar-oncopeptides-i-samband-med-q3-rapporten\/","title":{"rendered":"Redeye intervjuar Oncopeptides i samband med Q3-rapporten"},"content":{"rendered":"

Redeye intervjuar Oncopeptides vd Sofia Heigis om Q3-rapporten, sommarperiodens p\u00e5verkan p\u00e5 f\u00f6rs\u00e4ljningen av Pepaxti, f\u00f6rberedelser inf\u00f6r EU-kommissionens beslut om tredje linjens behandling samt glioblastomprogrammet.<\/p>\n

Se intervjun h\u00e4r<\/a><\/strong><\/p>\n","protected":false},"featured_media":8492,"template":"","meta":{"_acf_changed":false},"news_categories":[365],"protected-content":[],"class_list":["post-8491","news","type-news","status-publish","has-post-thumbnail","hentry","news_categories-investerare"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news\/8491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media\/8492"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=8491"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=8491"},{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=8491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}